garp
Abbvie acquires immune-oncology target from argenx
April 21, 2016Research and Development, Sales and Marketing AbbVie, Protein, argenx, garp, immuno-oncology, immunosuppresive
AbbVie (NYSE:ABBV) has announced the acquisition of a new preclinical-stage human antibody program evaluating the novel immune-oncology target GARP, a …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
